Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Etoricoxib (Arcoxia)].

P Leclercq1, M G Malaise

  • 1Université de Liège.

Revue Medicale De Liege
|July 24, 2004
PubMed
Summary
This summary is machine-generated.

Etoricoxib, a selective COX-2 inhibitor NSAID, offers effective pain and inflammation relief for arthritis. It demonstrates comparable efficacy to traditional NSAIDs but with a reduced risk of gastro-intestinal side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An unusual submucosal lesion.

Acta gastro-enterologica Belgica·2025
Same author

Evaluation of patient reported outcome measures and costs of managing osteoarthritis of the hip.

Acta orthopaedica Belgica·2024
Same author

Umbilical spider's web.

Acta gastro-enterologica Belgica·2022
Same author

[About a pediatric patients cohort followed in the adult rheumatology department of CHU Liège].

Revue medicale de Liege·2021
Same author

[Remarkable medical advances in rheumatology : may be…].

Revue medicale de Liege·2020
Same author

Immune profile at HIV infection diagnosis: Evolution in the French Alps area over the last 20 years.

Medecine et maladies infectieuses·2019
Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026
Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026
Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026
Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026
Same journal

[Climate change and skin].

Revue medicale de Liege·2026
Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026
See all related articles

Area of Science:

  • Pharmacology
  • Rheumatology
  • Gastroenterology

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
  • Selective cyclo-oxygenase-2 (COX-2) inhibitors offer an alternative to traditional NSAIDs with potentially fewer gastro-intestinal adverse effects.
  • Etoricoxib is a novel NSAID targeting COX-2 with high selectivity.

Purpose of the Study:

  • To evaluate the efficacy and safety of etoricoxib in managing inflammatory conditions.
  • To compare etoricoxib's COX-1/COX-2 selectivity with other COX-2 selective NSAIDs.
  • To establish recommended dosages for various arthritic conditions.

Main Methods:

  • Review of comparative studies on etoricoxib efficacy and safety.
  • Assessment of COX-1/COX-2 selectivity ratios.

Related Experiment Videos

  • Dosage recommendations based on clinical data for osteoarthritis, rheumatoid arthritis, and gouty arthritis.

    • Main Results:

    • Etoricoxib exhibits high selectivity for COX-2 over COX-1.
    • Comparative studies show etoricoxib's efficacy is similar to non-selective NSAIDs.
    • Etoricoxib is associated with fewer gastro-intestinal adverse effects compared to traditional NSAIDs.

    Conclusions:

    • Etoricoxib is an effective NSAID for managing osteoarthritis, rheumatoid arthritis, and acute gouty arthritis.
    • Its high COX-2 selectivity profile contributes to a favorable gastro-intestinal safety profile.
    • Etoricoxib represents a valuable therapeutic option in the management of inflammatory arthropathies.